Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

por Stewart, A. Keith, Krishnan, Amrita Y., Singhal, Seema, Boccia, Ralph V., Patel, Manish R., Niesvizky, Ruben, Chanan-Khan, Asher A., Ailawadhi, Sikander, Brumm, Jochen, Mundt, Kirsten E., Hong, Kyu, McBride, Jacqueline, Shon-Nguyen, Quyen, Xiao, Yuanyuan, Ramakrishnan, Vanitha, Polson, Andrew G., Samineni, Divya, Leipold, Douglas, Humke, Eric W., McClellan, James Scott, Berdeja, Jesus G.
Publicado 2019